Stay updated with breaking news from Jane Lowe Meisel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jane Lowe Meisel, MD, presents data from a retrospective study investigating patient characteristics, treatment patterns, and clinical outcomes for tucatinib-based treatment in the real-world setting both overall and following fam-trastuzumab deruxtecan (T-DXd).
Jane Lowe Meisel, MD, discusses previously reported data from the ELAINE-1 and ELAINE-2 trials, their significance within the ESR1-mutant, ER-positive, HER2-negative breast cancer treatment paradigm, and the purpose of the ongoing ELAINE-3 trial.
Practice-changing therapy for HER2-low breast cancer, potential for some women to skip surgery
JScreen’s CancerGEN screening program is a lifesaver.
“To prevent cancer on a wide scale, accessible genetic testing is key,” says Jane Lowe Meisel, MD, Associate Professor of Hematology and Medical Oncology at Emory University School of Medicine. “Cancer genetic testing makes prevention and early detection possible.”